Genoptix Says Lab Expansion Will Cost 20 Percent More Than Originally Expected

The specialized clinical lab disclosed the new expansion cost — but not that it represents and increase — in its third-quarter earnings release, which showed a 58-percent rise in revenue and a 40-percent increase in net loss.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.